These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 16198197

  • 1. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [Abstract] [Full Text] [Related]

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC.
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [Abstract] [Full Text] [Related]

  • 3. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [Abstract] [Full Text] [Related]

  • 4. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR, Chen L.
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [Abstract] [Full Text] [Related]

  • 5. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
    Laruelle M, Kegeles LS, Abi-Dargham A.
    Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442
    [Abstract] [Full Text] [Related]

  • 6. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M.
    Pol J Pharmacol; 2003 Nov; 55(2):133-54. PubMed ID: 12926541
    [Abstract] [Full Text] [Related]

  • 7. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia.
    Steullet P, Neijt HC, Cuénod M, Do KQ.
    Neuroscience; 2006 Feb; 137(3):807-19. PubMed ID: 16330153
    [Abstract] [Full Text] [Related]

  • 8. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC, Seamans JK.
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA, Bustamante ML, Silva H, Aboitiz F.
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [Abstract] [Full Text] [Related]

  • 10. Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex.
    Del Arco A, Mora F.
    Pharmacol Biochem Behav; 2008 Aug; 90(2):226-35. PubMed ID: 18508116
    [Abstract] [Full Text] [Related]

  • 11. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T, Mouri A, Murai R, Noda Y.
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [Abstract] [Full Text] [Related]

  • 12. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M, Czyrak A, Wedzony K.
    Psychiatr Pol; 2000 Nov; 34(4):607-21. PubMed ID: 11059260
    [Abstract] [Full Text] [Related]

  • 13. Pathophysiologically based treatment interventions in schizophrenia.
    Lewis DA, Gonzalez-Burgos G.
    Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
    [Abstract] [Full Text] [Related]

  • 14. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K, Iyo M.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [Abstract] [Full Text] [Related]

  • 15. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
    Large CH.
    J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
    [Abstract] [Full Text] [Related]

  • 16. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H.
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [Abstract] [Full Text] [Related]

  • 17. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [Abstract] [Full Text] [Related]

  • 18. Schizophrenia: from dopaminergic to glutamatergic interventions.
    Laruelle M.
    Curr Opin Pharmacol; 2014 Feb; 14():97-102. PubMed ID: 24524997
    [Abstract] [Full Text] [Related]

  • 19. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia.
    Ramsey AJ.
    Prog Brain Res; 2009 Feb; 179():51-8. PubMed ID: 20302817
    [Abstract] [Full Text] [Related]

  • 20. Glutamatergic aspects of schizophrenia.
    Tamminga C.
    Br J Psychiatry Suppl; 1999 Feb; (37):12-5. PubMed ID: 10211134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.